Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Moderna Files for Conditional Marketing Approval for its COVID-19 Vaccine in Adolescents in the European Union
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today […]
Advent France Biotechnology (AFB) Appoints Sidonie Fabre as CFO
Advent France Biotechnology (AFB), an AMF-regulated investment company dedicated to life sciences, today announces the […]
Local Chemists and Pharmacies Taking on Amazon
From today over 400 high street pharmacy stores will be better equipped to drive online […]
UnitedHealthcare Awards $275,000 in Maternal Health Grants to Seven Community Organizations in Louisiana
UnitedHealthcare Community Plan of Louisiana has awarded $275,000 in maternal health grants to seven community […]
Novartis Announces Iptacopan Met Phase II Study Primary Endpoint in Rare Kidney Disease IgA Nephropathy (IgAN)
Novartis today announced Phase II primary endpoint data showing investigational iptacopan (LNP023) – a first-in-class, […]
Oxford/AstraZeneca Alternative Now Available at Riverside Vaccination Centre
Vaccination appointments are available for residents who are eligible at the Riverside Vaccination Centre in […]
‘We Can Treat It’: Mortality Rate of Rare Condition Linked to AstraZeneca Shot Plunges
Doctors are now confident they can detect and treat the rare blood clotting syndrome associated […]
Apple Advances Personal Health by Introducing Secure Sharing and New Insights
Apple today previewed advanced consumer health and wellness insights for users, as well as new tools for […]
Tollys Presents Scientific Data Supporting Preclinical Proof of Concept for TL-532, Its Cancer Immunotherapy Drug Candidate
Tollys, a biopharmaceutical company developing TL-532, the first synthetic specific agonist of Toll-like Receptor 3 […]
Calquence Demonstrated Fewer Incidences of Atrial Fibrillation Versus Ibrutinib in Previously Treated Patients with Chronic Lymphocytic Leukaemia and Sustained Patient Benefit at Four Years in the Front-line Setting
Final results from the head-to-head ELEVATE-RR Phase III trial of AstraZeneca’s Calquence (acalabrutinib) demonstrated non-inferior […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more